<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00107783</url>
  </required_header>
  <id_info>
    <org_study_id>050076</org_study_id>
    <secondary_id>05-HG-0076</secondary_id>
    <nct_id>NCT00107783</nct_id>
  </id_info>
  <brief_title>Long-Term Study of Nitisinone to Treat Alkaptonuria</brief_title>
  <official_title>Long-Term Clinical Trial of Nitisinone in Alkaptonuria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Human Genome Research Institute (NHGRI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This 3-year study will examine the safety and effectiveness of long-term use of nitisinone
      (Orfadin) for treating joint problems in patients with alkaptonuria, an inherited disease in
      which a compound called homogentisic acid accumulates. The excess homogentisic acid causes
      arthritis and limited joint movement. It can also cause heart valve damage and kidney stones.

      Patients between 30 and 80 years of age with alkaptonuria may be eligible for this study.
      Patients must have hip involvement, but at least one remaining hip joint. Candidates are
      recruited from among patients enrolled in protocol 00-HG-0141, &quot;Clinical, Biochemical, and
      Molecular Investigations into Alkaptonuria.&quot; Participants may enter both protocols
      simultaneously.

      Participants are randomly assigned to one of two treatment groups: one group takes their
      regular medicines plus a 2-mg nitisinone capsule daily; the other group takes only their
      regular medicines. Patients taking nitisinone have blood tests to measure liver function 2
      weeks and 6 weeks after starting treatment. Before starting therapy, all patients are
      admitted to the NIH Clinical Center for 4-5 days to undergo the following procedures:

        -  Medical history and physical examination

        -  24-hour urine collection to test for sugar, protein, and other molecules

        -  Blood tests for liver and thyroid function, blood counts, and blood chemistries

        -  Blood and urine tests to measure tyrosine and other amino acids and homogentisic acid

        -  Bone x-rays

        -  Spiral CT (computed tomography) of the abdomen to detect kidney stones

        -  Eye examination and evaluations by specialists in rehabilitation medicine and pain, plus
           other consults in skin, brain, lung, heart, and kidney, as needed

      All patients, whether or not they receive nitisinone, return to the Clinical Center for a 2-3
      day follow-up admission every 4 months for a history and physical examination, blood tests,
      and two 24-hour urine collections. Every 12 months (12, 24 and 36 months after starting the
      study), patients also have repeat bone x-rays, spiral CT, kidney ultrasound, echocardiogram,
      and electrocardiogram. An MRI of the brain is done at the end of the study.

      Sixteen months after the end of the study enrollment period, the treated and non-treated
      groups are evaluated. If nitisinone has delayed the progression of joint disease in the
      treated group, the study continues and all patients receive the drug for the remainder of the
      study. If not, the study continues for another 20 months, at which time the study ends and
      the evaluation process is repeated.

      Patients who develop symptoms such as corneal crystals, pain, or severe liver or nervous
      system toxicity may be taken off the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Alkaptonuria is a rare metabolic disease in which homogentisic acid (HGA), an intermediary
      metabolite in tyrosine catabolism, accumulates due to deficiency of the enzyme homogentisic
      acid oxidase. Patients with alkaptonuria exhibit homogentisic aciduria and ochronosis, or
      dark pigmentation of various tissues due to binding of HGA and its oxidized metabolites. The
      ochronosis results in debilitating destruction of cartilage, arthritis, lumbosacral
      ankylosis, limitation of motion, and bone deterioration in later life. No effective therapy
      exists for alkaptonuria. However, a compound named 2-(2-nitro-4-trifluoromethylbenzoyl) - 1,
      3-cyclohexanedione (nitisinone, NTBC, Orfadin) inhibits 4-hydroxyphenylpyruvate dioxygenase,
      the enzyme that produces HGA. Nitisinone, at doses of approximately 1 mg/kg/day, has proven
      safe and effective in tyrosinemia type I, which causes fatal liver disease in infants and
      children. Under protocol 97-HG-0201, we treated 9 alkaptonuria patients with nitisinone; for
      the 7 who received 1.05 mg twice daily, the HA fell from 4.0 plus or minus 1.8 g/24h to 0.2
      plus or minus 0.2 g/24h (normal 0.028 plus or minus 0.015 g/24h, n=10). Plasma tyrosine
      levels rose from 67 plus or minus 18 micro M to 760 plus or minus 181 micro M. The current
      protocol (05-HG-0076) is a randomized, controlled clinical trial to determine if nitisinone
      (2 mg daily) is beneficial for the joint symptoms of alkaptonuira. Patients are examined at
      the NIH Clinical Research Center every 4 months for 3 years. Hip joint range of motion serves
      as the primary outcome parameter, and nitisinone (Orfadin) is provided by Swedish Orphan
      International through an IND obtained by William A. Gahl. Forty patients (20 with nitisinone
      treatment and 20 untreated) have been enrolled for at least 16 months, and an interim
      analysis shows promising results. Serious adverse events in patients on nitisinone have
      included a death from myocardial infarction, keratopathy, and elevated liver function tests
      related to gallstones.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Total ROM Worse Hip.</measure>
    <time_frame>Measured at baseline and at 36 months</time_frame>
    <description>Change from baseline in the total (external + internal) hip range of motion (ROM) in the worse hip at 36 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Schober's Test</measure>
    <time_frame>Measured at baseline and at 36 months</time_frame>
    <description>Change from baseline of Schober's test at 36 months. Schober's test measures a patient's ability to flex his/her lower back. The examiner makes a mark at L5 (fifth lumbar vertebra) and places one finger 5 cm below and another finger 10 cm above this mark. The patient is asked to touch his/her toes. The examiner measures the increase in distance between the two fingers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Functional Reach Assessment</measure>
    <time_frame>Measured at baseline and at 36 months</time_frame>
    <description>Change from baseline of functional reach assessment at 36 months. Functional reach assessment measures the difference between the length of a person's outstretched arm and their maximal reach forward, while maintaining balance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Timed Get up and go</measure>
    <time_frame>Measured at baseline and at 36 months</time_frame>
    <description>Change from baseline of timed get up and go at 36 months. In timed get up and go, the patient is asked to stand up from a standard chair and walk a distance of 3 meters, turn around and walk back to the chair and sit down. The examiner measures the time it takes for the patient to perform this series of tasks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 6 Minute Walk Test (6MWT)</measure>
    <time_frame>Measured at baseline and at 36 months</time_frame>
    <description>Change from baseline of the 6MWT at 36 months. The 6MWT measures the distance that a patient can quickly walk on a flat hard surface in a period of six minutes.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Alkaptonuria</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nitisinone-treated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received nitisinone 2 mg orally, once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitisinone (NTBC)</intervention_name>
    <description>Treatment</description>
    <arm_group_label>Nitisinone-treated</arm_group_label>
    <other_name>Orfadin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

          -  Age 30-80 years, either gender

          -  Diagnosis of alkaptonuria based upon urinary HGA excretion greater than 0.4 g/24h

          -  At least one hip joint remaining

          -  Some evidence of hip involvement, e.g., pain or decreased range of motion

          -  Ability to travel to the NIH Clinical Research Center for admissions

          -  Ability to consent

          -  Availability of local medical follow-up

        EXCLUSION CRITERIA:

          -  Age less than 30 or greater than 80

          -  Non-alkaptonuria causes of ochronosis

          -  Bilateral hip joint replacement

          -  Keratopathy

          -  Contact lenses

          -  Uncontrolled glaucoma

          -  History of myocardial infarction

          -  History of emphysema or pulmonary insufficiency (Forced vital capacity less than 70%)

          -  Psychiatric illness or neurological disease that interferes with compliance or
             communication with health care personnel

          -  Current malignancy

          -  Open skin lesions

          -  Dietary habits or use of homeopathic therapies that interfere with tyrosine
             catabolism. The diet must be reasonably balanced, as determined by a dietician.

          -  Uncontrolled hypertension (blood pressure greater than 180 systolic or greater than 95
             diastolic)

          -  History of extreme alcohol abuse or sever liver disease

          -  Liver greater than 3 cm below the right costal margin

          -  Electrocardiogram changes indicative of myocardial infarction, arrhythmia,
             tachycardia, bradycardia, left bundle branch block

          -  Chest radiographic abnormalities, including an infiltrate, mass, congestive heart
             failure, embolism, atelectasis

          -  Serum postassium less than 3. 0 mEq/L

          -  Serum creatinine greater than 2.0 mg/dL

          -  SGPT greater than 41 U/L or SGOT greater than 34 U/L

          -  CK greater than 500 U/L

          -  Hemoglobin less than 10.0 g/dL

          -  Platelets less than 100 k/mm(3)

          -  WBC less than 3.0 k/microL

          -  T4 greater than 15 microg/dL

          -  T4 less than 4 microg/dL

          -  ESR greater than 100 mm/h

          -  Plasma tyrosine greater than 150 microM
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2005-HG-0076.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Introne WJ, Phornphutkul C, Bernardini I, McLaughlin K, Fitzpatrick D, Gahl WA. Exacerbation of the ochronosis of alkaptonuria due to renal insufficiency and improvement after renal transplantation. Mol Genet Metab. 2002 Sep-Oct;77(1-2):136-42.</citation>
    <PMID>12359141</PMID>
  </reference>
  <reference>
    <citation>Phornphutkul C, Introne WJ, Perry MB, Bernardini I, Murphey MD, Fitzpatrick DL, Anderson PD, Huizing M, Anikster Y, Gerber LH, Gahl WA. Natural history of alkaptonuria. N Engl J Med. 2002 Dec 26;347(26):2111-21.</citation>
    <PMID>12501223</PMID>
  </reference>
  <reference>
    <citation>Janocha S, Wolz W, Srsen S, Srsnova K, Montagutelli X, Guénet JL, Grimm T, Kress W, Müller CR. The human gene for alkaptonuria (AKU) maps to chromosome 3q. Genomics. 1994 Jan 1;19(1):5-8.</citation>
    <PMID>8188241</PMID>
  </reference>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2005</study_first_submitted>
  <study_first_submitted_qc>April 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2005</study_first_posted>
  <results_first_submitted>December 20, 2010</results_first_submitted>
  <results_first_submitted_qc>December 20, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 19, 2011</results_first_posted>
  <last_update_submitted>December 20, 2010</last_update_submitted>
  <last_update_submitted_qc>December 20, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2011</last_update_posted>
  <responsible_party>
    <name_title>William A. Gahl, M.D./National Human Genome Research Institute</name_title>
    <organization>National Institutes of Health</organization>
  </responsible_party>
  <keyword>Arthritis</keyword>
  <keyword>Homogentisic Acid</keyword>
  <keyword>Corneal Damage</keyword>
  <keyword>Tyrosine</keyword>
  <keyword>Alkaptonuria</keyword>
  <keyword>Photophobia</keyword>
  <keyword>Nitisinone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alkaptonuria</mesh_term>
    <mesh_term>Ochronosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitisinone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were enrolled at the NIH Clinical Center between April 2005 and March 2006.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Control</title>
          <description>No treatment</description>
        </group>
        <group group_id="P2">
          <title>Nitisinone-treated</title>
          <description>Subjects received nitisinone 2 mg orally, once daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Second hip replacement</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control</title>
          <description>No treatment</description>
        </group>
        <group group_id="B2">
          <title>Nitisinone-treated</title>
          <description>Subjects received nitisinone 2 mg orally, once daily.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.3" spread="6.5"/>
                    <measurement group_id="B2" value="52.2" spread="7.9"/>
                    <measurement group_id="B3" value="51.7" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Range of Motion (ROM) Worse Hip</title>
          <description>The total (internal + external) range of motion (ROM) of the worse hip.</description>
          <units>degrees</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.4" spread="16.1"/>
                    <measurement group_id="B2" value="39.0" spread="12.7"/>
                    <measurement group_id="B3" value="42.7" spread="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Schober's test</title>
          <description>Schober's test measures a patient's ability to flex his/her lower back. The examiner makes a mark at L5 (fifth lumbar vertebra) and places one finger 5 cm below and another finger 10 cm above this mark. The patient is asked to touch his/her toes. The examiner measures the increase in distance between the two fingers.</description>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.42" spread="1.04"/>
                    <measurement group_id="B2" value="10.86" spread="0.73"/>
                    <measurement group_id="B3" value="11.14" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Functional Reach Assessment</title>
          <description>Functional reach assessment measures the difference between the length of a person's outstretched arm and their maximal reach forward, while maintaining balance.</description>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.22" spread="2.92"/>
                    <measurement group_id="B2" value="8.98" spread="3.10"/>
                    <measurement group_id="B3" value="9.60" spread="3.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Timed get up and go</title>
          <description>In timed get up and go, the patient is asked to stand up from a standard chair and walk a distance of 3 meters, turn around and walk back to the chair and sit down. The examiner measures the time it takes for the patient to perform this series of tasks.</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.56" spread="1.40"/>
                    <measurement group_id="B2" value="9.70" spread="4.10"/>
                    <measurement group_id="B3" value="8.63" spread="3.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>6 minute walk test</title>
          <description>The 6MWT measures the distance that a patient can quickly walk on a flat hard surface in a period of six minutes.</description>
          <units>ft</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1578" spread="205"/>
                    <measurement group_id="B2" value="1336" spread="369"/>
                    <measurement group_id="B3" value="1457" spread="319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Total ROM Worse Hip.</title>
        <description>Change from baseline in the total (external + internal) hip range of motion (ROM) in the worse hip at 36 months.</description>
        <time_frame>Measured at baseline and at 36 months</time_frame>
        <population>Intention to treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>No treatment</description>
          </group>
          <group group_id="O2">
            <title>Nitisinone-treated</title>
            <description>Subjects received nitisinone 2 mg orally, once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total ROM Worse Hip.</title>
          <description>Change from baseline in the total (external + internal) hip range of motion (ROM) in the worse hip at 36 months.</description>
          <population>Intention to treat.</population>
          <units>degrees</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.1" spread="24.7"/>
                    <measurement group_id="O2" value="1.6" spread="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Schober's Test</title>
        <description>Change from baseline of Schober's test at 36 months. Schober's test measures a patient's ability to flex his/her lower back. The examiner makes a mark at L5 (fifth lumbar vertebra) and places one finger 5 cm below and another finger 10 cm above this mark. The patient is asked to touch his/her toes. The examiner measures the increase in distance between the two fingers.</description>
        <time_frame>Measured at baseline and at 36 months</time_frame>
        <population>In the control group, two patients who dropped out for personal reasons were not included in this analysis, and in the treated group one patient who died was not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>No treatment</description>
          </group>
          <group group_id="O2">
            <title>Nitisinone-treated</title>
            <description>Subjects received nitisinone 2 mg orally, once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Schober's Test</title>
          <description>Change from baseline of Schober's test at 36 months. Schober's test measures a patient's ability to flex his/her lower back. The examiner makes a mark at L5 (fifth lumbar vertebra) and places one finger 5 cm below and another finger 10 cm above this mark. The patient is asked to touch his/her toes. The examiner measures the increase in distance between the two fingers.</description>
          <population>In the control group, two patients who dropped out for personal reasons were not included in this analysis, and in the treated group one patient who died was not included in this analysis.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.06" spread="1.33"/>
                    <measurement group_id="O2" value=".12" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Functional Reach Assessment</title>
        <description>Change from baseline of functional reach assessment at 36 months. Functional reach assessment measures the difference between the length of a person's outstretched arm and their maximal reach forward, while maintaining balance.</description>
        <time_frame>Measured at baseline and at 36 months</time_frame>
        <population>In the control group, two patients who dropped out for personal reasons were not included in this analysis, and in the treated group one patient who died was not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>No treatment</description>
          </group>
          <group group_id="O2">
            <title>Nitisinone-treated</title>
            <description>Subjects received nitisinone 2 mg orally, once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Functional Reach Assessment</title>
          <description>Change from baseline of functional reach assessment at 36 months. Functional reach assessment measures the difference between the length of a person's outstretched arm and their maximal reach forward, while maintaining balance.</description>
          <population>In the control group, two patients who dropped out for personal reasons were not included in this analysis, and in the treated group one patient who died was not included in this analysis.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.21" spread="3.81"/>
                    <measurement group_id="O2" value="-1.86" spread="3.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Timed Get up and go</title>
        <description>Change from baseline of timed get up and go at 36 months. In timed get up and go, the patient is asked to stand up from a standard chair and walk a distance of 3 meters, turn around and walk back to the chair and sit down. The examiner measures the time it takes for the patient to perform this series of tasks.</description>
        <time_frame>Measured at baseline and at 36 months</time_frame>
        <population>In the control group, two patients who dropped out for personal reasons were not included in this analysis, and in the treated group one patient who died was not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>No treatment</description>
          </group>
          <group group_id="O2">
            <title>Nitisinone-treated</title>
            <description>Subjects received nitisinone 2 mg orally, once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Timed Get up and go</title>
          <description>Change from baseline of timed get up and go at 36 months. In timed get up and go, the patient is asked to stand up from a standard chair and walk a distance of 3 meters, turn around and walk back to the chair and sit down. The examiner measures the time it takes for the patient to perform this series of tasks.</description>
          <population>In the control group, two patients who dropped out for personal reasons were not included in this analysis, and in the treated group one patient who died was not included in this analysis.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.54" spread="1.84"/>
                    <measurement group_id="O2" value="-1.33" spread="5.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in 6 Minute Walk Test (6MWT)</title>
        <description>Change from baseline of the 6MWT at 36 months. The 6MWT measures the distance that a patient can quickly walk on a flat hard surface in a period of six minutes.</description>
        <time_frame>Measured at baseline and at 36 months</time_frame>
        <population>In the control group, two patients who dropped out for personal reasons were not included in this analysis, and in the treated group one patient who died was not included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Control</title>
            <description>No treatment</description>
          </group>
          <group group_id="O2">
            <title>Nitisinone-treated</title>
            <description>Subjects received nitisinone 2 mg orally, once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in 6 Minute Walk Test (6MWT)</title>
          <description>Change from baseline of the 6MWT at 36 months. The 6MWT measures the distance that a patient can quickly walk on a flat hard surface in a period of six minutes.</description>
          <population>In the control group, two patients who dropped out for personal reasons were not included in this analysis, and in the treated group one patient who died was not included in this analysis.</population>
          <units>ft</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" spread="356"/>
                    <measurement group_id="O2" value="169" spread="591"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>36 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Control</title>
          <description>No treatment</description>
        </group>
        <group group_id="E2">
          <title>Nitisinone-treated</title>
          <description>Subjects received nitisinone 2 mg orally, once daily.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (13.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>atrial fibrillation</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>keratitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>corneal irritation due to tyrosine crystal deposition</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>bile duct stone</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>liver enzyme elevation</sub_title>
                <description>High elevations of alanine transaminase (ALT); ALT &gt; 123 U/L.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>sarcoidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>accidental overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>muscle injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (13.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>sensorineural hearing loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>elevated liver enzymes</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Mild elevations in alanine transaminase (ALT); ALT between 41 and 100 U/L.</description>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>upper respiratory infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>skin rash</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small number of patients involved in study and several patients dropped out; primary outcome parameter selection possibly inappropriate because hip joint damage that is already present may be irreversible.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>William Gahl, MD/Clinical Director</name_or_title>
      <organization>NHGRI</organization>
      <phone>301-402-2739</phone>
      <email>gahlw@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

